Imagion Biosystems Ltd Total Liabilities
Imagion Biosystems Ltd total liabilities. Based on the latest financial reports, Imagion Biosystems Ltd (IBX) has total liabilities worth AU$4.21 Million AUD (≈ $2.98 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IBX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Imagion Biosystems Ltd (2014–2025)
Total liabilities of Imagion Biosystems Ltd from 2014 to 2025. This chart illustrates how Imagion Biosystems Ltd's total liabilities have evolved over time, based on quarterly financial data.
Imagion Biosystems Ltd Competitors by Total Liabilities
The table below lists competitors of Imagion Biosystems Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AOTI Inc
LSE:AOTI
|
UK | GBX36.64 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$4.50 Million |
|
Sonoro Energy Ltd
V:SNV
|
Canada | CA$722.91K |
|
Interactive Strength Inc. Common Stock
NASDAQ:TRNR
|
USA | $40.45 Million |
|
Panther Metals Ltd
AU:PNT
|
Australia | AU$137.29K |
|
Rainbow Rare Earths Limited
LSE:RBW
|
UK | GBX12.88 Million |
|
CDN Maverick Capital Corp.
F:338B
|
Germany | €349.51K |
|
Northern 2 Vct Plc
LSE:NTV
|
UK | GBX207.00K |
Liability Composition Analysis (2014–2025)
This chart breaks down Imagion Biosystems Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Imagion Biosystems Ltd (IBX) total assets.
Liquidity & Leverage Metrics
Imagion Biosystems Ltd Total Liabilities Ratios Explained
Imagion Biosystems Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imagion Biosystems Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imagion Biosystems Ltd (2014–2025)
The table below shows the annual total liabilities of Imagion Biosystems Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | AU$4.21 Million ≈ $2.98 Million |
-17.31% |
| 2024-12-31 | AU$5.09 Million ≈ $3.60 Million |
-39.26% |
| 2023-12-31 | AU$8.37 Million ≈ $5.93 Million |
+58.06% |
| 2022-12-31 | AU$5.30 Million ≈ $3.75 Million |
+554.19% |
| 2021-12-31 | AU$809.88K ≈ $573.04K |
-32.80% |
| 2020-12-31 | AU$1.21 Million ≈ $852.71K |
-36.52% |
| 2019-12-31 | AU$1.90 Million ≈ $1.34 Million |
+44.02% |
| 2018-12-31 | AU$1.32 Million ≈ $932.73K |
+91.39% |
| 2017-12-31 | AU$688.77K ≈ $487.35K |
+52.39% |
| 2016-12-31 | AU$451.99K ≈ $319.81K |
-95.32% |
| 2015-12-31 | AU$9.65 Million ≈ $6.83 Million |
+123.93% |
| 2014-12-31 | AU$4.31 Million ≈ $3.05 Million |
-- |
About Imagion Biosystems Ltd
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing th… Read more